Nicholas Company Inc. Buys 15,135 Shares of AtriCure, Inc. $ATRC

Nicholas Company Inc. lifted its stake in AtriCure, Inc. (NASDAQ:ATRC) by 8.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 192,635 shares of the medical device company’s stock after acquiring an additional 15,135 shares during the period. Nicholas Company Inc.’s holdings in AtriCure were worth $6,313,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Teacher Retirement System of Texas boosted its holdings in shares of AtriCure by 5.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 7,512 shares of the medical device company’s stock worth $246,000 after buying an additional 385 shares during the period. Riverwater Partners LLC bought a new stake in shares of AtriCure during the 2nd quarter worth $1,103,000. Envestnet Asset Management Inc. boosted its holdings in shares of AtriCure by 3.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 58,460 shares of the medical device company’s stock worth $1,916,000 after buying an additional 1,804 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of AtriCure during the 2nd quarter worth $318,000. Finally, WCM Investment Management LLC boosted its holdings in shares of AtriCure by 69.4% during the 2nd quarter. WCM Investment Management LLC now owns 327,498 shares of the medical device company’s stock worth $10,572,000 after buying an additional 134,146 shares during the period. 99.11% of the stock is owned by institutional investors.

Insider Buying and Selling at AtriCure

In other AtriCure news, Director Sven Wehrwein sold 5,000 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $37.00, for a total value of $185,000.00. Following the sale, the director owned 34,374 shares of the company’s stock, valued at $1,271,838. The trade was a 12.70% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Vinayak Doraiswamy sold 2,500 shares of the business’s stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $36.58, for a total transaction of $91,450.00. Following the completion of the sale, the insider directly owned 71,872 shares in the company, valued at $2,629,077.76. This trade represents a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 17,952 shares of company stock worth $655,633. Corporate insiders own 3.50% of the company’s stock.

Wall Street Analysts Forecast Growth

ATRC has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AtriCure in a report on Wednesday, October 8th. Canaccord Genuity Group lifted their price target on AtriCure from $53.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday. BTIG Research set a $54.00 price target on AtriCure in a research report on Wednesday, July 30th. Wall Street Zen raised AtriCure from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Finally, Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research report on Thursday. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $52.22.

AtriCure Stock Performance

ATRC opened at $34.56 on Friday. The stock has a market cap of $1.72 billion, a PE ratio of -56.65 and a beta of 1.59. The company has a current ratio of 3.94, a quick ratio of 2.83 and a debt-to-equity ratio of 0.16. AtriCure, Inc. has a 1 year low of $28.29 and a 1 year high of $43.11. The stock’s 50 day simple moving average is $36.03 and its 200-day simple moving average is $33.95.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.10. The firm had revenue of $134.27 million for the quarter, compared to analyst estimates of $131.25 million. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.56%. The business’s revenue for the quarter was up 15.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. Sell-side analysts forecast that AtriCure, Inc. will post -0.6 EPS for the current year.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.